PRNewswire (Tue, 14-Apr 7:30 AM ET)
Market Chameleon (Thu, 9-Apr 5:51 AM ET)
PRNewswire (Thu, 9-Apr 7:30 AM ET)
PRNewswire (Tue, 31-Mar 4:15 PM ET)
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
PRNewswire (Fri, 30-Jan 4:15 PM ET)
Galmed Pharmaceuticals Unveils Potent Anti-Tumor Drug Synergy, Eyes Early-2026 Phase 1b Trial
Market Chameleon (Tue, 18-Nov 5:32 AM ET)
Market Chameleon (Mon, 17-Nov 4:53 AM ET)
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
Galmed Pharmaceuticals Ltd. - trades on the NASDAQ stock market under the symbol GLMD.
As of April 30, 2026, GLMD stock price was flat at $0.56 with 18,474 million shares trading.
GLMD has a beta of 1.93, meaning it tends to be more sensitive to market movements. GLMD has a correlation of 0.10 to the broad based SPY ETF.
GLMD has a market cap of $3.69 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, GLMD traded as high as $93.60 and as low as $.41.
GLMD has underperformed the market in the last year with a price return of -59.1% while the SPY ETF gained +30.1%. GLMD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -25.3% and -20.2%, respectively, while the SPY returned +3.1% and +2.0%, respectively.
GLMD support price is $.52 and resistance is $.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GLMD shares will trade within this expected range on the day.
